copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Efficacy of Bempedoic Acid, Novel Treatment for Elevated LDL . . . By Anthony Rice Bempedoic acid is a novel non-statin drug produced by Esperion Therapeutics to treat hypercholesterolemia, elevated levels of low-density lipoprotein (LDL) cholesterol in the blood 1 In the double-blind, placebo-controlled, phase 3 2022 CLEAR Outcomes trial conducted by Esperion, bempedoic acid treatment was associated with reductions in major adverse cardiovascular events
Comparative Cardiovascular Benefits of Bempedoic Acid and . . . Background In the CLEAR (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) Outcomes trial, treatment of statin-intolerant patients with bempedoic acid produced a 21% decrease in low-density lipoprotein cholesterol (LDL-C) relative to placebo and a 13% relative reduction in the risk of major adverse cardiovascular events
Bempedoic Acid - StatPearls - NCBI Bookshelf Bempedoic acid is a lipid-lowering agent pivotal in managing patients with elevated low-density lipoprotein cholesterol (LDL-C) levels The U S Food and Drug Administration (FDA) has sanctioned its use as an adjunct to maximally tolerated statin therapy for the reduction of LDL-C, specifically in individuals afflicted by atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial
Comprehensive review of statin-intolerance and the practical . . . Bempedoic acid (BA), an ATP citrate lyase inhibitor, decreases hepatic generation of cholesterol, upregulates low-density lipoprotein (LDL) receptor expression in the liver, and eventually clears circulating LDL-cholesterol from the blood Multiple randomized clinical trials studying BA demonstrate a reduction in LDL levels by 17–28 % in SI
Bempedoic acid in the management of lipid disorders and . . . Bempedoic acid, the first in-class inhibitor of ATP-citrate lyase presents a new approach to lipid-lowering therapy By reducing the endogenous production of cholesterol, upstream of the rate-limiting enzyme HMG-CoA-reductase, i e , the target of statins, bempedoic acid reduces circulating plasma concentrations of low-density lipoprotein cholesterol (LDL-C), and major adverse CVD events (MACE
Reshaping Dyslipidaemia Treatment with Bempedoic Acid—A . . . Apolipoprotein B, total cholesterol, and non-HDL-C were also reduced, particularly in the combination therapy, while hsCRP was reduced particularly in the monotherapy group with 180 mg bempedoic acid (40%) [32]
PATIENT-CENTERED EDUCATION FROM THE NATIONAL LIPID . . . Bempedoic acid interferes with an enzyme in the liver that regulates cholesterol production It allows for increased clearance of LDL-C from the blood stream leading to lower levels Bempedoic acid is only active within the liver cells and not in skeletal muscle Therefore, it can be used in patients who have had prior statin associated muscle symptoms
(PDF) Bempedoic Acid: A Novel Approach in Managing . . . This review concludes that bempedoic acid represents a significant advancement in lipid-lowering therapy, offering a valuable option for patients with hypercholesterolemia, particularly those with
Bempedoic Acid: A New Approach to Lowering LDL Cholesterol What is Bempedoic Acid? Bempedoic acid is a novel cholesterol-lowering drug specifically designed to reduce LDL cholesterol in the blood Unlike statins, which have been the standard treatment for decades, bempedoic acid works through a different mechanism, making it a promising option for people who cannot tolerate statins Classified as an ATP-citrate lyase inhibitor, bempedoic acid blocks a